Angiogenesis - Special Issue: Angiogenesis Inhibitors in Combinatorial Approaches

Guest Edited by Patrycja Nowak-Sliwinska and Arjan W. Griffioen, this special issue of Angiogenesis focusses on the combination of angiostatic strategies with other treatment modalities. It is generally expected that improvement of disease therapy will be in the combination of treatments. Many treatment modalities are involved in these innovative combined strategies, i.e. targeted drugs, immune modulators, epi-genetic agents, microRNAs, or radiotherapy.

Angiogenesis inhibitors in combinatorial approaches. Patrycja Nowak-Sliwinska, Arjan W. Griffioen.

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Rakesh R. Ramjiawan, Arjan W. Griffioen, Dan G. Duda

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Teele Kuusk, Laurence Albiges, Bernard Escudier, et al.

The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Lisanne C. Hamming, Ben J. Slotman, Henk M. W. Verheul, et al.

Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. MariaRosa Bani, Alessandra Decio, Raffaella Giavazzi, et al.

Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Robert H. Berndsen, U. Kulsoom Abdul, Andrea Weiss, et al.

miRNAs: micro-managers of anticancer combination therapies. Judy R. van Beijnum, Elisa Giovannetti, Dennis Poel, et al.

Photograph by Patrycja Nowak-Sliwinska.